154 related articles for article (PubMed ID: 19217525)
1. Tumor targeting and SPECT imaging properties of an (111)In-labeled galectin-3 binding peptide in prostate carcinoma.
Deutscher SL; Figueroa SD; Kumar SR
Nucl Med Biol; 2009 Feb; 36(2):137-46. PubMed ID: 19217525
[TBL] [Abstract][Full Text] [Related]
2. 111In-labeled galectin-3-targeting peptide as a SPECT agent for imaging breast tumors.
Kumar SR; Deutscher SL
J Nucl Med; 2008 May; 49(5):796-803. PubMed ID: 18413389
[TBL] [Abstract][Full Text] [Related]
3. In vitro and in vivo evaluation of ⁶⁴Cu-radiolabeled KCCYSL peptides for targeting epidermal growth factor receptor-2 in breast carcinomas.
Kumar SR; Gallazzi FA; Ferdani R; Anderson CJ; Quinn TP; Deutscher SL
Cancer Biother Radiopharm; 2010 Dec; 25(6):693-703. PubMed ID: 21204764
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of an 111In-radiolabeled peptide as a targeting and imaging agent for ErbB-2 receptor expressing breast carcinomas.
Kumar SR; Quinn TP; Deutscher SL
Clin Cancer Res; 2007 Oct; 13(20):6070-9. PubMed ID: 17947470
[TBL] [Abstract][Full Text] [Related]
5. Receptor-binding, biodistribution, dosimetry, and micro-SPECT/CT imaging of 111In-[DTPA(1), Lys(3), Tyr(4)]-bombesin analog in human prostate tumor-bearing mice.
Ho CL; Chen LC; Lee WC; Chiu SP; Hsu WC; Wu YH; Yeh CH; Stabin MG; Jan ML; Lin WJ; Lee TW; Chang CH
Cancer Biother Radiopharm; 2009 Aug; 24(4):435-43. PubMed ID: 19694578
[TBL] [Abstract][Full Text] [Related]
6. [
Vats K; Chakraborty A; Rakshit S; Damle A; Sarma HD; Satpati D
Nucl Med Biol; 2023; 118-119():108331. PubMed ID: 36933456
[TBL] [Abstract][Full Text] [Related]
7. In-labeled KCCYSL peptide as an imaging probe for ErbB-2-expressing ovarian carcinomas.
Deutscher SL; Figueroa SD; Kumar SR
J Labelled Comp Radiopharm; 2009 Dec; 52(14):583-590. PubMed ID: 20976123
[TBL] [Abstract][Full Text] [Related]
8. (64)Cu-labeled peptide for PET of breast carcinomas expressing the Thomsen-Friedenreich carbohydrate antigen.
Kumar SR; Gallazzi FA; Quinn TP; Deutscher SL
J Nucl Med; 2011 Nov; 52(11):1819-26. PubMed ID: 21984800
[TBL] [Abstract][Full Text] [Related]
9. Pegylated Arg-Gly-Asp peptide: 64Cu labeling and PET imaging of brain tumor alphavbeta3-integrin expression.
Chen X; Hou Y; Tohme M; Park R; Khankaldyyan V; Gonzales-Gomez I; Bading JR; Laug WE; Conti PS
J Nucl Med; 2004 Oct; 45(10):1776-83. PubMed ID: 15471848
[TBL] [Abstract][Full Text] [Related]
10. Affinity maturation of an ERBB2-targeted SPECT imaging peptide by in vivo phage display.
Larimer BM; Thomas WD; Smith GP; Deutscher SL
Mol Imaging Biol; 2014 Aug; 16(4):449-58. PubMed ID: 24550054
[TBL] [Abstract][Full Text] [Related]
11. Modification of the structure of a metallopeptide: synthesis and biological evaluation of (111)In-labeled DOTA-conjugated rhenium-cyclized alpha-MSH analogues.
Cheng Z; Chen J; Miao Y; Owen NK; Quinn TP; Jurisson SS
J Med Chem; 2002 Jul; 45(14):3048-56. PubMed ID: 12086490
[TBL] [Abstract][Full Text] [Related]
12. In vivo evaluation and small-animal PET/CT of a prostate cancer mouse model using 64Cu bombesin analogs: side-by-side comparison of the CB-TE2A and DOTA chelation systems.
Garrison JC; Rold TL; Sieckman GL; Figueroa SD; Volkert WA; Jurisson SS; Hoffman TJ
J Nucl Med; 2007 Aug; 48(8):1327-37. PubMed ID: 17631556
[TBL] [Abstract][Full Text] [Related]
13. "To serve and protect": enzyme inhibitors as radiopeptide escorts promote tumor targeting.
Nock BA; Maina T; Krenning EP; de Jong M
J Nucl Med; 2014 Jan; 55(1):121-7. PubMed ID: 24287321
[TBL] [Abstract][Full Text] [Related]
14. Molecular imaging, pharmacokinetics, and dosimetry of In-AMBA in human prostate tumor-bearing mice.
Ho CL; Liu IH; Wu YH; Chen LC; Chen CL; Lee WC; Chuang CH; Lee TW; Lin WJ; Shen LH; Chang CH
J Biomed Biotechnol; 2011; 2011():101497. PubMed ID: 21660132
[TBL] [Abstract][Full Text] [Related]
15. Bifunctional phage-based pretargeted imaging of human prostate carcinoma.
Newton-Northup JR; Figueroa SD; Quinn TP; Deutscher SL
Nucl Med Biol; 2009 Oct; 36(7):789-800. PubMed ID: 19720291
[TBL] [Abstract][Full Text] [Related]
16. Imaging of prostate cancer with immuno-PET and immuno-SPECT using a radiolabeled anti-EGP-1 monoclonal antibody.
van Rij CM; Sharkey RM; Goldenberg DM; Frielink C; Molkenboer JD; Franssen GM; van Weerden WM; Oyen WJ; Boerman OC
J Nucl Med; 2011 Oct; 52(10):1601-7. PubMed ID: 21865288
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of
Banerjee SR; Kumar V; Lisok A; Plyku D; Nováková Z; Brummet M; Wharram B; Barinka C; Hobbs R; Pomper MG
J Nucl Med; 2019 Mar; 60(3):400-406. PubMed ID: 30237212
[TBL] [Abstract][Full Text] [Related]
18. Novel series of 111In-labeled bombesin analogs as potential radiopharmaceuticals for specific targeting of gastrin-releasing peptide receptors expressed on human prostate cancer cells.
Hoffman TJ; Gali H; Smith CJ; Sieckman GL; Hayes DL; Owen NK; Volkert WA
J Nucl Med; 2003 May; 44(5):823-31. PubMed ID: 12732685
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the pharmacokinetic effects of various linking group using the 111In-DOTA-X-BBN(7-14)NH2 structural paradigm in a prostate cancer model.
Garrison JC; Rold TL; Sieckman GL; Naz F; Sublett SV; Figueroa SD; Volkert WA; Hoffman TJ
Bioconjug Chem; 2008 Sep; 19(9):1803-12. PubMed ID: 18712899
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
